Breaking News
November 16, 2018 - Many RA patients’ pain related to central nervous system
November 16, 2018 - Changes in Himalayan gut microbiomes linked to diet
November 16, 2018 - Inhibition of prostaglandin E2 enhances ability to combat infectious colitis
November 16, 2018 - Chronic dry eye can slow reading rate and disrupt day to day tasks
November 16, 2018 - Researchers develop new drug molecule that inhibits inflammation
November 16, 2018 - Dementia symptoms peak in winter and spring, study finds
November 16, 2018 - Stanford tobacco researcher weighs in on JUUL
November 16, 2018 - Increasing omega-3 fatty acid intake during pregnancy reduces risk of premature birth, review finds
November 16, 2018 - Researchers find no link between infants waking up at night and later developmental problems
November 16, 2018 - Both parents and children agree about confidential medical services
November 16, 2018 - FDA warns against use of unapproved pain medications with implanted pumps
November 16, 2018 - Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
November 16, 2018 - Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
November 16, 2018 - Inexpensive, portable air purifier could help protect the heart from pollution
November 16, 2018 - New 15-minute scan could help diagnose brain damage in babies up to two years old
November 16, 2018 - Deep brain stimulation not effective for treating early Alzheimer’s
November 16, 2018 - Traditional chemotherapy superior to new alternative for oropharyngeal cancers | News Center
November 16, 2018 - What This Pond Protist Does With Its Genome Will Astound You
November 15, 2018 - Researchers develop tool that speeds up analysis and publication of biomedical data
November 15, 2018 - Scientists identify mechanism used by lung cancer cells to obtain glucose
November 15, 2018 - Abnormalities in development of the brain could be involved in onset of autism, finds new study
November 15, 2018 - Soy protein equally effective as animal protein in building muscle strength
November 15, 2018 - American Academy of Pediatrics, Nov. 2-6
November 15, 2018 - Dopamine drives early addiction to heroin
November 15, 2018 - Variance in gut microbiome in Himalayan populations linked to dietary lifestyle | News Center
November 15, 2018 - Reducing Cardiovascular Disease: The Amish Way
November 15, 2018 - King’s researchers launch charter to guide organizations to engage abuse survivors in research
November 15, 2018 - Enable Injections enters into development agreements with UCB and Apellis Pharmaceuticals
November 15, 2018 - TGen North collaborates with NARBHA Institute to advance human health
November 15, 2018 - Researchers discover molecular basis for therapeutic actions of an African folk medicine
November 15, 2018 - Human Cell Atlas study of early pregnancy shows how mother’s immune system is modified
November 15, 2018 - New guidelines for detecting and managing sarcopenia to be launched in the UK
November 15, 2018 - Researchers explore role of dietary composition on energy expenditure
November 15, 2018 - Elsevier launches Entellect™ Platform, unlocking value by creating AI-ready life sciences data
November 15, 2018 - Now that cannabis is legal in Canada, let’s use it to tackle the opioid crisis
November 15, 2018 - In the Spotlight: At the intersection of tech, health, and ethics
November 15, 2018 - Traditional Glaucoma Test Can Miss Severity of the Disease
November 15, 2018 - Researchers directly connect activities of genes with instinctive behavior in male cichlids
November 15, 2018 - Salk researchers report new methods to identify AD drug candidates with anti-aging properties
November 15, 2018 - St. Jude Hospital announces availability of largest collections of leukemia samples
November 15, 2018 - Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline
November 15, 2018 - Designing a novel cell-permeable peptide chimera to promote wound healing
November 15, 2018 - NEI investigators combine two imaging modalities to view the retina in unprecedented detail
November 15, 2018 - Determining how hearts develop to better understand congenital heart defects
November 15, 2018 - Maverick immune cells can act independently to identify and kill cancer cells, finds research
November 15, 2018 - Advanced AI and big data methods to tackle dementia
November 15, 2018 - Report reveals increase in pancreatic cancer death rates across Europe
November 15, 2018 - Luxia Scientific announces availability of its gut microbiome test in Luxembourg
November 15, 2018 - New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis
November 15, 2018 - New approach targets matrix surrounding neurons to protect neurons after stroke
November 15, 2018 - Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine
November 15, 2018 - Heart failure patients shouldn’t stop meds even if condition improves: study
November 15, 2018 - Parents and carers of people with diabetes experience emotional or mental health problems
November 15, 2018 - RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders
November 15, 2018 - Breakthrough research could lead to a new wave of cancer-fighting antibodies
November 15, 2018 - Mylan and Biocon launch new insulin glargine biosimilar in the UK
November 15, 2018 - For wildfire safety, only particular masks guard against toxic particulate matter
November 15, 2018 - New study of tribe shows influence of Western diet and lifestyle on blood pressure
November 15, 2018 - Scientists harness power of natural killer cells to treat children with neuroblastoma
November 15, 2018 - Investigating foodborne disease outbreak in Bosnia and Herzegovina based on simulation game
November 15, 2018 - Recommendations Issued for Management of Bradycardia
November 15, 2018 - Benefit unclear due to a lack of suitable studies
November 15, 2018 - TAMEST recognizes UT Southwestern’s Ralph DeBerardinis for changing our understanding of cancer
November 15, 2018 - Researchers discover key factors behind intestinal inflammation in CVID patients
November 15, 2018 - CityU develops first microarrayed 3D neuronal culture platform
November 15, 2018 - Expert suggests ways to control uncomfortable vaginal symptoms in diabetic women
November 15, 2018 - New edition of Red Journal focuses on roles of imaging in radiation oncology
November 15, 2018 - Doctors Aren’t Promoting Breastfeeding’s Cancer-Protection Benefit
November 15, 2018 - Collection of demonstration projects highlights value of patient engagement in research
November 15, 2018 - Technique to ‘listen’ to a patient’s brain during tumour surgery
November 15, 2018 - Seven-year-old returns to life as a “normal, healthy child” following bone marrow transplant
November 15, 2018 - AMSBIO expands range of high quality FFPE cancer cell line controls
November 15, 2018 - Marijuana use by kidney donors has no effect on transplant outcomes
November 15, 2018 - Exploring NMR Spectroscopy Applications through Interesting Infographics
November 15, 2018 - Chapman University wins additional $2.9 million NIH grant to study Alzheimer’s disease
November 15, 2018 - Microgel powder reduces infection and promotes healing
November 15, 2018 - Suicidal patients with prescribed access to psychotropic drugs should be closely monitored
November 15, 2018 - Nitric oxide-releasing technology shows potential to reduce healing time of diabetic foot ulcers
November 15, 2018 - Mass shootings may trigger unnecessary blood donations
November 15, 2018 - From heart disease to cancer: New study tracks shift of county death rates
Investigational drug targeting the opioid system may help reduce symptoms of major depression

Investigational drug targeting the opioid system may help reduce symptoms of major depression

image_pdfDownload PDFimage_print

Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment. The results of these Phase 3 trials of a drug combining buprenorphine with samidorphan are reported today in Molecular Psychiatry by a research team led by a Massachusetts General Hospital physician.

“Less than 40 percent of patients with major depression achieve symptom remission from first-line treatment with today’s antidepressant drugs, which target monoamine-based neural signaling,” explains Maurizio Fava, MD executive director of the Clinical Trials Network & Institute in the MGH Department of Psychiatry and senior author of the Molecular Psychiatry report. “Having a new class of antidepressants with a novel mechanism of action could have significant impact for patients with persistent symptoms.” Fava also led the Phase 2 trial of this drug combination, which was published in 2016 and identified the effectiveness of the highest dosage level tested in the current trials.

The endogenous opioid system – the neurological pathways that interact with opioid drugs – is believed to have a role in several factors that can be affected in clinical depression – including mood, motivation and social functions. PET imaging studies have suggested that opioid system circuits may be dysregulated in patients with major depression. While low doses of buprenorphine – an opioid used for both pain relief and in medication-assisted treatment for opioid addiction – had beneficial effects in a multicenter trial in patients with major depression, a major challenge to its use for depression treatment is the risk of abuse and dependence.

The combination of buprenorphine with samidorphan, which blocks one of the opioid receptors activated by buprenorphine, was designed to reduce the abuse and dependence potential of buprenorphine alone. The drug – also called ALKS 5461 – is being developed by Alkermes, Inc., which sponsored the two trials, called FORWARD-4 and FORWARD-5, conducted at a total of 111 sites in several countries. FORWARD-4 compared two dosage levels – either 0.5 mg of each drug or 2.0 mg of each – with a placebo; and FORWARD-5 compared 1.0 mg and 2.0 mg doses with a placebo. A total of almost 800 adult patients who had not responded adequately to at least 8 weeks of antidepressant treatment enrolled and continued taking their standard antidepressant throughout the trial period.

Since trials of depression drugs often elicit a significant placebo effect, both trials were designed in a way to reduce that risk. During the first stage of both randomized trials, participants received their assigned doses of either the active drug or a placebo for 5 weeks, at the end of which they completed a standard depression symptom assessment. Although neither participants nor the research team members with whom they directly interacted knew individual patients’ group assignments, other team members examined assessments from those receiving a placebo, identifying those in whom symptom reduction indicated a placebo effect.

Placebo group members who did not show symptom improvement were re-randomized either to continue receiving the placebo or to receive one of the tested doses of the active drug for the remaining 6 weeks of the trial. Again, they were not aware that their study medication had been changed. Other participants – both those receiving an active drug and those who were responding to the placebo – continued with the same medication during the second phase.

At the end of both trials, participants receiving the 2.0 mg doses of both active drugs had a greater reduction in depression symptoms than did those receiving a placebo. Those receiving 1.0 mg doses showed symptom reduction greater than the placebo group but less than the 2.0 mg doses, and the 0.5 mg-dose recipients had results no better than those of the placebo group. Although the differences between the 2.0 mg dosages and placebo in FORWARD-4 were not statistically significant, combining the results from both trials produced a significant effect.

Reported adverse effects – such as nausea, sleepiness, dizziness and fatigue – were mild to moderate and usually disappeared within a few days. There were no reports of participants’ taking excess doses, developing dependence or experiencing withdrawal symptoms. After their trial, participants were able to enroll in a long-term safety study of combined buprenorphine/samidorphan. Interim data from that study were presented at the American Psychiatric Association annual meeting in May 2018.

“Based on the safety profile observed with buprenorphine/samidorphan, we could have an important new pharmacological tool for patients with major depression who do not respond to standard therapies,” says Fava, the Slater Family Professor of Psychiatry at Harvard Medical School.

Source:

https://www.massgeneral.org/about/pressrelease.aspx?id=2307

Tagged with:

About author

Related Articles